Highlights frameworks for early lung cancer detection pathways which intersect with bronchoscopic diagnostic procedures in underserved populations.
Abstract
BACKGROUND: Lung cancer (LC) is the most common cause of cancer death in the UK and worldwide, but screening with low-dose CT (LDCT) reduces LC deaths. The UK National Screening Committee has recommended nationwide roll-out of LDCT screening, but the optimal risk thresholds for eligibility remain uncertain. METHODS: We conducted a cost-effectiveness analysis in the Yorkshire Lung Screening Trial (YLST) population comparing three eligibility criteria: US Preventive Services Task Force (USPSTF), Prostate Lung Colorectal and Ovarian study (PLCO)≥1.51% and Liverpool Lung Project model (LLP)≥5%. A Markov model estimated a no-screening counterfactual. Scenario analyses assessed how increasing PLCO(1.51%-7%) and LLP(5%-9%) thresholds affected LC detection, costs and quality-adjusted life years (QALYs). Payouts per detected LC were calculated using mortality and utility estimates from the literature and cost data from the trial. RESULTS: Incremental cost-effectiveness ratios (ICERs) versus no screening were £3949 (USPSTF), £3797 (LLP≥5%) and £4013 (PLCO≥1.51%). PLCOyielded the largest numbers screened and LCs detected, most QALYs gained and highest incremental net monetary benefit. Raising LLPand PLCOthresholds reduced both ICERs and QALYs gained. CONCLUSION: All three screening eligibility criteria are cost-effective according to the UK's willingness to pay threshold of £20 000/QALY. Within the range of thresholds observed in YLST, PLCOthresholds between ≥1.51% and ≥4% offered the most efficient cost-benefit trade-offs. Evidence suggests that lowering thresholds further would detect more LC cases while remaining cost-effective. These findings support the criteria implemented in YLST, but do not by themselves identify the optimal screening threshold for the wider UK population. TRIAL REGISTRATION NUMBER: ISRCTN42704678.
Keep reading
N opens the next oneDirectly impacts IP practice by highlighting the critical role of bronchoscopic sampling techniques in providing adequate tissue for molecular profiling.
Highlights the critical importance of obtaining adequate tissue via bronchoscopic biopsies for comprehensive molecular profiling.
Relevant to ablative therapies often managed or co-evaluated by interventional pulmonologists in the multidisciplinary management of lung malignancies.
Relevant for IP specialists involved in the bronchoscopic and image-guided tissue diagnosis and staging of apical lung masses.
Relevant to IP practices managing pulmonary nodules discovered during staging or diagnostic workups.